Gemcitabine elaidate: Cytotoxic agent oncolytic

Drugs of the Future

Volumn 36, Issue 6, 2011, Pages 427-432

  Venugopal, B ^a   Evans, T R J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CO 1 01; CO 101; CP 4126; ELACYTARABINE; GEMCITABINE; GEMCITABINE ELAIDATE; NUCLEOSIDE TRANSPORTER; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; COLON CANCER; DEATH; DISEASE FREE INTERVAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG STRUCTURE; FATIGUE; FIRST PASS EFFECT; HUMAN; LETHARGY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 84952983939     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.06.1608941     Document Type: Review

References (27)

1. Borretzen, B., Dalen, A., Myhren, F., Sandvold, M.L. (Norsk Hydro AS). Gemcitabine derivatives. EP 0986570, JP 2001509160, US 2002042391, US 6384019, WO 1998032762.
2. Burris, H.A., Moore, M.J., Andersen, J. et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997, 15(6): 2403-13. (Pubitemid 27251144)
3. Von der Maase, H., Hansen, S.W., Roberts, J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18(17): 3068-77.
4. Schiller, J.H., Harrington, D., Belani, C.P. et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346(2): 92-8. (Pubitemid 34438899)
5. Moore, M.J., Goldstein, D., Hamm, J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15): 1960-6. (Pubitemid 46972777)
6. Tabernero, J., Macarulla, T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: An opportunity for better clinical development. J Clin Oncol 2009, 27(33): 5487-91.
7. Mackey, J.R., Mani, R.S., Selner, M. et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58(19): 4349-57. (Pubitemid 28450036)
8. Heinemann, V., Hertel, L.W., Grindey, G.B., Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine. Cancer Res 1988, 48(14): 4024-31.
9. Huang, P., Chubb, S., Hertel, L.W., Grindey, G.B., Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51(22): 6110-7.
10. Veltkamp, S.A., Pluim, D., Van Eijndhoven, M.A.J. et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′- difluorodeoxyuridine. Mol Cancer Ther 2008, 7(8): 2415-25.
11. Heinemann, V., Xu, Y.Z., Chubb, S., Sen, A., Hertel, L.W., Grindey, G.B., Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990, 38(4): 567-72. (Pubitemid 20356209)
12. Bergman, A.M., Pinedo, H.M., Peters, G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updates 2002, 5(1): 19-33.
13. Zhang, J., Visser, F., King, K., Baldwin, S., Young, J., Cass, C. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metast Rev 2007, 26(1): 85-110. (Pubitemid 46452184)
14. Damaraju, V.L., Damaraju, S., Young, J.D., Baldwin, S.A., Mackey, J., Sawyer, M.B., Cass, C.E. Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003, 22(47): 7524-36. (Pubitemid 37487174)
15. Spratlin, J., Sangha, R., Glubrecht, D. et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004, 10(20): 6956-61. (Pubitemid 39383046)
16. Giovannetti, E., Del Tacca, M., Mey, V. et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006, 66(7): 3928-35.
17. Farrell, J.J., Elsaleh, H., Garcia, M. et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1): 187-95.
18. Bergman, A., Adema, A., Balzarini, J. et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 2011, 29(3):: 1-11.
19. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 2577.
20. Clavis Pharma Technology. http://www.clavispharma.com/Technology. Accessed December 29, 2010.
21. Dueland, S., Aamdal, S., Lind, M.J., Thomas, H., Liland Sandvold, M., Gaullier, J.-M., Rasch, W. Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study. Acta Oncol 2009, 48(1): 137-45.
22. Burke, A., Swords, S., Kelly, K., Giles, F.J. Elacytarabine. Drugs Fut 2009, 34(12): 941.
23. Galmarini, C.M., Myhren, F., Sandvold, M.L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009, 144(2): 273-5.
24. rd Eur Soc Med Oncol (ESMO) Congr (Sept 12-16, Stockholm) 2008] 2008, 19(Suppl. 8): Abst 496P.
25. ndEORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 16-19, Berlin) 2010, Poster 426.
26. Veltkamp, S.A., Jansen, R.S., Callies, S. et al. Oral administration of gemcitabine in patients with refractory tumors: A clinical and pharmacologic study. Clin Cancer Res 2008, 14(11): 3477-86.
27. A study comparing CO-1.01 with gemcitabine as first line therapy in patients with metastatic pancreatic adenocarcinoma (NCT01124786). ClinicalTrials.gov Web site, May 31, 2011.